Exagen Inc (XGN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Exagen Inc stock (XGN) is currently trading at $2.88. Exagen Inc PS ratio (Price-to-Sales) is 0.99. Analyst consensus price target for XGN is $9.50. WallStSmart rates XGN as Sell.
- XGN PE ratio analysis and historical PE chart
- XGN PS ratio (Price-to-Sales) history and trend
- XGN intrinsic value — DCF, Graham Number, EPV models
- XGN stock price prediction 2025 2026 2027 2028 2029 2030
- XGN fair value vs current price
- XGN insider transactions and insider buying
- Is XGN undervalued or overvalued?
- Exagen Inc financial analysis — revenue, earnings, cash flow
- XGN Piotroski F-Score and Altman Z-Score
- XGN analyst price target and Smart Rating
Exagen Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Exagen Inc (XGN) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, revenue growth, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Exagen Inc (XGN) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Strong revenue growth at 21.80% annually
59.65% held by institutions, strong professional interest
Supporting Valuation Data
Exagen Inc (XGN) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.9x book value
Exagen Inc (XGN) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 8.7/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth, Institutional Own.. Valuation metrics including Price/Sales (0.99) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 21.80%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Book (3.87) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -147.80%, Operating Margin at -29.90%, Profit Margin at -30.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -147.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 21.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
XGN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
XGN's Price-to-Sales ratio of 0.99x trades at a deep discount to its historical average of 4.01x (12th percentile). The current valuation is 94% below its historical high of 17.98x set in Dec 2019, and 62% above its historical low of 0.61x in Apr 2024. Over the past 12 months, the PS ratio has compressed from ~1.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Exagen Inc (XGN) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Exagen Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 67M with 22% growth year-over-year. The company is currently unprofitable, posting a -30.0% profit margin.
Key Findings
The company is unprofitable with a -30.0% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Exagen Inc maintain 22%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.91, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Exagen Inc.
Bottom Line
Exagen Inc offers an attractive blend of growth (22% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Exagen Inc(XGN)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name in the United States. The company is headquartered in Vista, California.